Fiasp® Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Long-term
Lisbon, Portugal (ots/PRNewswire) - Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings[4]. (Logo: ...